title: The skin remodeling in type 1 diabetes and insulin resistance animal models.
abstract: The skin matrix metalloproteinase 3, tissue inhibitors of matrix metalloproteinase 2 and collagen III content changes in type 1 diabetes and insulin resistance treated with insulin and metformin were studied. Healthy adult male Wistar rats were obtained from experimental animal house, Department of Experimental Pharmacology, Medical University in Bialystok. The rats were divided randomly into five groups of 8 rats each. Control rats were injected intraperitoneally by NaCl. Type IDDM was induced by a single injection of Streptozocin. Insulin resistance was induced by a high-fat diet. The chosen groups of rats were also treated with insulin or metformin. ELISA Kits (USCN Life Science, China) were used to measure content of matrix metallo-proteinase 3 (ELISA Kit for Matrix Metalloproteinase 3 - MMP3), tissue inhibitor of matrix metalloproteinase 2 (ELISA Kit for Tissue Inhibitors of Metalloproteinase 2 - TIMP2) and content of collagen type 3 (ELISA Kit for Collagen Type III - COL3). The results were reported as a median. The statistical significance was defined as p<0.05. Type 1 diabetes and insulin resistance have significantly reduced the quality of the skin, shown by the increase in content of matrix metalloproteinase 3 and the decrease in content of tissue inhibitors of matrix metalloproteinase 2. Type 1 diabetes and insulin resistance have reduced the quality of the skin expressed by type III collagen content decrease but for future studies it is recommend to determine rat interstitial collagenase, MMP-13, as well. Insulin and metformin treatment improved the quality of the diabetic skin, demonstrated by the type III collagen content increase.
authors.affiliation: Institute of Health Care, Higher Vocational School, Suwalki, Poland; Research Laboratory of Cosmetology, Medical University of Bialystok, Poland. katarzyna.wolosik@umb.edu.pl.
authors.forename: M
authors.initials: M
authors.lastname: Knaś
authors.forename: K
authors.initials: K
authors.lastname: Wołosik
authors.forename: A
authors.initials: A
authors.lastname: Zalewska
authors.forename: A
authors.initials: A
authors.lastname: Mikucka-Niczyporuk
authors.forename: I
authors.initials: I
authors.lastname: Kasacka
authors.forename: M
authors.initials: M
authors.lastname: Niczyporuk
mesh_terms: D000818:Animals; D024061:Collagen Type III / Q000378:metabolism*; D003238:Connective Tissue / Q000503:physiopathology*; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology*; D007328:Insulin; D007333:Insulin Resistance; D008297:Male; D019278:Matrix Metalloproteinase 3 / Q000378:metabolism*; D008687:Metformin; D011897:Random Allocation; D017208:Rats, Wistar; D012867:Skin / Q000378:metabolism / Q000503:physiopathology*; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000378:metabolism; D019717:Tissue Inhibitor of Metalloproteinase-3 / Q000378:metabolism
chemical_list: D024061:Collagen Type III; D007328:Insulin; D019717:Tissue Inhibitor of Metalloproteinase-3; D019716:Tissue Inhibitor of Metalloproteinase-2; D008687:Metformin; D019278:Matrix Metalloproteinase 3